Anticoagulation bridging therapy patterns in patients undergoing total hip or total knee replacement in a us health plan: Real-world observations and implications

American Health and Drug Benefits

Volumn 4, Issue 4, 2011, Pages

  Baser, Onur ^a   Supina, Dylan ^a   Sengupta, Nishan ^a   Li, Wang ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MONOTHERAPY; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 80052715450     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bulger CM, Jacobs C, Patel NH. Epidemiology of acute deep vein thrombosis. Tech Vasc Interv Radiol. 2004;7:50-54.
2. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg. 2003;25:1-5.
3. Michota F. Venous thromboembolism: epidemiology, characteristics, and consequences. Clin Cornerstone. 2005;7:8-15.
4. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
5. US Department of Health and Human Services. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism 2008. Washington, DC: US Department of Health and Human Services. http://www.surgeongeneral.gov/topics/ deepvein/calltoaction/call-to-action-on-dvt-2008.pdf. Accessed January 18, 2011.
6. Warwick D, Dahl OE, Fisher WD. Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg Br. 2008;90:127-132.
7. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359: 938-949.
8. Kurtz S, Ong K, Lau E, Mowat F, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780-785.
9. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th Edition. Chest. 2008;133: 381S-453S.
10. Johanson NA, Lachiewicz PF, Lieberman JR, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am. 2009;91:1756-1757.
11. National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guideline No. 92; http://www.nice.org.uk/guidance/index.jsp?action=byID&o=12695. Accessed July 4, 2010.
12. Parvizi J, Azzam K, Rothman RH. Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines. J Arthroplasty. 2008;23:2-5.
13. American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism in Patients Undergoing Total Hip or Knee Arthroplasty. Adopted by the American Academy of Orthopedic Surgeons Board of Directors May 2007. http://www.aaos.org/research/guidelines/PE_guideline.pdf. Accessed January 18, 2011.
14. Caprini JA, Tapson VF, Hyers TM, et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg. 2005;42:726-733.
15. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324:1865-1875.
16. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
17. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996; 49:1429-1433.
18. Baser O, Palmer L, Stephenson J. The estimation power of alternative comorbidity indices. Value Health. 2008;11:946-955.
19. US Department of Labor. Bureau of Labor Statistics. Consumer price index. Measuring price change for medical care in the CPI. http://data.bls.gov/cpi/cpi fact4.htm. Accessed January 18, 2011.
20. Heckman JJ. Econometric causality. Int Stat Rev. 2008;76:1-27.
21. Baser O. Choosing propensity score matching over regression adjustment for causal inference: when, why and how it makes sense. J Med Econ. 2007;10:379-391.
22. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006;9:377-385.
23. Baser O, Crown WH, Pollicino C. Guidelines for selecting among different types of bootstraps. Curr Med Res Opin. 2006;22:799-808.
24. Office of the Legislative Counsel for the US House of Representatives. Compilation of Patient Protection and Affordable Care Act. May 2010. http://docs.house.gov/energycommerce/ppacacon.pdf. Accessed January 18, 2011.
25. Centers for Medicare & Medicaid Services, US Department of Health and Human Services. CMS improves patient safety for Medicare and Medicaid by addressing never events. http://www.cms.gov/apps/media/press/factsheet.asp?Counter=3224 &intNumPerPage=10&checkDate=&checkKey=&srchType=1&numDays=0&srch Opt=0&srchData=&keywordType=All&chkNewsType=6&intPage=&showAll=1&pYear=1&year=2008&desc=false&cboOrder=date. Accessed January 18, 2011.
26. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119(1 suppl):176S-193S.
27. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003;124: 386S-392S.
28. Caprini JA, Hyers TM. Compliance with antithrombotic guidelines. Manag Care. 2006;15:49-50,53-60,66. 29.
29. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878-1886.